ASMS 2020 Reboot kicks off a two-week live program on June 1st! We’ve been busy preparing behind the scenes and look forward to sharing our revolutionary technology with the global …
The most common therapeutic strategy for drug development is the inhibition of enzymatic activity, which has many challenges, including the relatively limited protein repertoire available to be targeted (only 20-25% …
Chemical cross-linking of interacting proteins locks them in place, and when combined with MS based proteomics, facilitates the identification of tertiary and quaternary structural information. This powerful approach allows researchers …
Ion mobility assisted precursor selection benefits cross-linking mass spectrometry. Read More »
The recent adoption of trapped ion mobility into the sensitive and ultra-high resolution Bruker TOF platform, has created a remarkably powerful instrument. The timsTOF Pro directly provides an accurate measure …
4D Proteomics enabled Maxquant demonstrates unprecedented depth of coverage. Read More »
As one of the immune system’s first lines of defence, Natural Killer (NK) cells – are a crucial part of the autoimmune response that can prevent the growth and spread …
Aurora Series columns help identify NK cell role in defeating cancer. Read More »
G-protein-coupled receptors (GPCRs) are the largest and most diverse classes of membrane receptors in humans. These cell surface receptors act like the switchboard of the cell, communicating messages in the …
The study of single cell -omics has generated enormous interest in the scientific field over the last few years. The analysis of complex biological systems at the single cell level …
Aurora Series columns advance single-cell proteomics. Read More »
**Updated 14-Aug-2020** On behalf of everyone here at IonOpticks, we hope that you are keeping safe and healthy at this challenging time. There is no doubt that the global research …
Recent advances in mass spectrometry technology have seen remarkable increases in proteomic sequencing speed, while improvements to dynamic range have remained limited. An exemplar of this is the new timsTOF …
IonOpticks, a medical research technology company backed by The Walter and Eliza Hall Institute of Medical Research is a proud recipient of a 2018 City of Melbourne Small Business grant. …
IonOpticks awarded City of Melbourne Business Expansion Grant. Read More »
A discovery about how human cells are ‘triggered’ to undergo an inflammatory type of cell death could have implications for treating cancer, stroke and tissue injury, and immune disorders. A …
Human immune trigger map paves way for better treatments. Read More »
